Isofraxidin是一种从 Sarcandra glabra (Thunb.) Nakai 草药中分离纯化的天然产物,具有显著的镇痛和抗炎活性,可能通过调节促炎细胞因子 TNF-α 和 p38 及 ERK1/2 的磷酸化来介导其作用。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Isofraxidin, a natural product isolated and purified from the herbs of Sarcandra glabra (Thunb.) Nakai, possesses significant analgesic and anti-inflammatory activities that may be mediated through the regulation of pro-inflammatory cytokines, TNF-α and the phosphorylation of p38 and ERK1/2. |
| Concentration | Treated Time | Description | References | |
| RAW 264.7 macrophages | 0.03, 0.06, and 0.06 mmol | 24 hours | To investigate the effect of C + R + I on LPS-induced inflammatory factors and oxidative stress in RAW 264.7 macrophages. Results showed that C + R + I significantly suppressed the levels of nitric oxide (NO), pro-inflammatory cytokines, and inhibited iNOS and COX-2 expression. | Front Pharmacol. 2021 Jan 11;11:580064 |
| Bone marrow-derived macrophages (BMMs) | 12.5 µM | 8 hours | To evaluate the effect of isofraxidin on RANKL-induced NFATc1 transcriptional activity, results showed that isofraxidin inhibited NFATc1 activation. | Cell Transplant. 2021 Jan-Dec;30:963689721990321 |
| Bone marrow-derived macrophages (BMMs) | 6.25 and 12.5 µM | 4 days | To evaluate the effect of isofraxidin on RANKL-induced osteoclast formation in BMMs, results showed that isofraxidin inhibited TRAP activity and osteoclast formation. | Cell Transplant. 2021 Jan-Dec;30:963689721990321 |
| Bone marrow-derived macrophages (BMMs) | 6.25 and 12.5 µM | 24 hours | To evaluate the effect of isofraxidin on BMMs cell viability, results showed that 6.25 and 12.5 µM concentrations did not affect cell viability. | Cell Transplant. 2021 Jan-Dec;30:963689721990321 |
| Administration | Dosage | Frequency | Description | References | ||
| BALB/c mice | Chronic unpredictable mild stress (CUMS)-induced depressive model | Oral gavage | 3, 10, 30 mg/kg | Once daily for 4 weeks | Isofraxidin significantly reversed CUMS-induced decrease in body weight gain, sucrose preference, locomotor activity, and increased immobility time in the forced swimming test (FST) and tail suspension test (TST). Additionally, isofraxidin decreased serum levels of corticosterone (CORT), adrenocorticotropic hormone (ACTH), and hypothalamic corticotropin-releasing hormone (CRH), suppressed the expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 in the hippocampus, and inhibited CUMS-induced activation of nuclear factor kappa B (NF-κB) and NOD-like receptor protein 3 (NLRP3) inflammasomes in the hippocampus. | Brain Sci. 2022 Oct 11;12(10):1376 |
| BALB/c mice | LPS-induced acute lung injury model | Intraperitoneal injection | High dose (50, 20, and 20 mg/kg), middle dose (25, 10, and 10 mg/kg), low dose (12.5, 5, and 5 mg/kg) | Once daily for three days | To investigate the protective effect of C + R + I on LPS-induced acute lung injury in mice. Results showed that C + R + I significantly alleviated lung histopathological damage, reduced inflammatory cell infiltration, and inhibited the activation of the MAPK-NF-κB signaling pathway. | Front Pharmacol. 2021 Jan 11;11:580064 |
| Swiss albino mice | LPS-induced cytokine release syndrome | Intraperitoneal | 15 mg/kg | Once daily for 3 days | Isofraxidin alone or in combination with methylprednisolone ameliorates LPS-induced inflammatory and oxidative stress damage in mice, reduces inflammatory and oxidative stress markers, and prevents LPS-induced liver and lung tissue damage. | Biomedicines. 2025 Mar 7;13(3):653 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
4.50mL 0.90mL 0.45mL |
22.50mL 4.50mL 2.25mL |
45.01mL 9.00mL 4.50mL |
|
| CAS号 | 486-21-5 |
| 分子式 | C11H10O5 |
| 分子量 | 222.19 |
| SMILES Code | O=C1C=CC2=CC(OC)=C(O)C(OC)=C2O1 |
| MDL No. | MFCD00221757 |
| 别名 | 异秦皮啶 |
| 运输 | 蓝冰 |
| InChI Key | HOEVRHHMDJKUMZ-UHFFFAOYSA-N |
| Pubchem ID | 5318565 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 250 mg/mL(1125.14 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1